

## DAFTAR PUSTAKA

- Adhiatma, D., Ali, I. and Ghoib, H., 2022. Interleukin-6 serum levels in metastatic breast cancer and non-metastatic breast cancer. *International Journal of Health Sciences*, 6, pp.3512-3520
- Al-Mazidi, S., Farhat, K., Nedjadi, T., Chaudhary, A., Zin Al-Abdin, O., Rabah, D., Al-Zoghaibi, M. and Djouhri, L., 2018. Association of interleukin-6 and other cytokines with self-reported pain in prostate cancer patients receiving chemotherapy. *Pain Medicine*, 19(5), pp.1058-1066
- Argyriou, A.A., Chroni, E., Koutras, A., Iconomou, G., Papapetropoulos, S., Polychronopoulos, P. and Kalofonos, H.P., 2006. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. *Journal of pain and symptom management*, 32(3), pp.237-244.
- Argyriou, A.A., Cavaletti, G., Briani, C., Velasco, R., Bruna, J., Campagnolo, M., Alberti, P., Bergamo, F., Cortinovis, D., Cazzaniga, M. and Santos, C., 2013. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. *Cancer*, 119(2), pp.438-444.
- Argyriou, A.A., Park, S.B., Islam, B., Tamburin, S., Velasco, R., Alberti, P., Bruna, J., Psimaras, D., Cavaletti, G. and Cornblath, D.R., 2019. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. *Journal of Neurology, Neurosurgery & Psychiatry*, 90(12), pp.1361-1369.
- Aromolaran, K.A. and Goldstein, P.A., 2017. Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy: Cause and effect?. *Molecular pain*, 13, p.1744806917714693.
- Baldwin, R.M., Owzar, K., Zembutsu, H., Chhibber, A., Kubo, M., Jiang, C., Watson, D., Eclow, R.J., Mefford, J., McLeod, H.L. and Friedman, P.N., 2012. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. *Clinical Cancer Research*, 18(18), pp.5099-5109.
- Bandos, H., Melnikow, J., Rivera, D.R., Swain, S.M., Sturtz, K., Fehrenbacher, L., Wade III, J.L., Brufsky, A.M., Julian, T.B., Margolese, R.G. and McCarron, E.C., 2018. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. *JNCI: Journal of the National Cancer Institute*, 110(2), p. djx162.
- Bower, J.E., Ganz, P.A., Irwin, M.R., Cole, S.W., Carroll, J., Kuhlman, K.R., Petersen, L., Garet, D., Asher, A., Hurvitz, S.A. and Crespi, C.M., 2022. Acute and chronic effects of adjuvant therapy on inflammatory markers in breast cancer patients. *JNCI cancer spectrum*, 6(4), p. pkac052.
- Boyette-Davis, J., Xin, W., Zhang, H. and Dougherty, P.M., 2011. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced

- hyperalgesia and can be prevented by treatment with minocycline. *Pain*<sup>®</sup>, 152(2), pp.308-313.
- Brandolini, L., Castelli, V., Aramini, A., Giorgio, C., Bianchini, G., Russo, R., De Caro, C., d'Angelo, M., Catanesi, M., Benedetti, E. and Giordano, A., 2019. DF2726A, a new IL-8 signalling inhibitor, can counteract chemotherapy-induced neuropathic pain. *Scientific reports*, 9(1), p.11729.
- Bromberg, J., and Wang, T.C., 2009. Inflammation and cancer: IL-6 and STAT3 complete the link. *Cancer cell*, 15(2), pp.79-80.
- Brown, T., Sykes, D. and Allen, A.R., 2021. Implications of breast cancer chemotherapy-induced inflammation on the gut, liver, and central nervous system. *Biomedicines*, 9(2), p.189.
- Campisi, J., 2013. Aging, cellular senescence, and cancer. *Annual review of physiology*, 75(1), pp.685-705
- Castel, H., Denouel, A., Lange, M., Tonon, M.C., Dubois, M. and Joly, F., 2017. Biomarkers associated with cognitive impairment in treated cancer patients: potential predisposition and risk factors. *Frontiers in pharmacology*, 8, p.138.
- Cavaletti, G. and Marmiroli, P., 2010. Chemotherapy-induced peripheral neurotoxicity. *Nature Reviews Neurology*, 6(12), pp.657-666.
- Chen, J., Wei, Y., Yang, W., Huang, Q., Chen, Y., Zeng, K. and Chen, J., 2022. IL-6: the link between inflammation, immunity, and breast cancer. *Frontiers in Oncology*, 12, p.903800.
- Chaudhry, V., Chaudhry, M., Crawford, T.O., Simmons-O'Brien, E. and Griffin, J.W., 2003. Toxic neuropathy in patients with pre-existing neuropathy. *Neurology*, 60(2), pp.337-340.
- Chen, E.I., Crew, K.D., Trivedi, M., Awad, D., Maurer, M., Kalinsky, K., Koller, A., Patel, P., Kim Kim, J. and Hershman, D.L., 2015. Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. *PloS one*, 10(12), p.e0145816.
- Cheung, Y.T., Ng, T., Shwe, M., Ho, H.K., Foo, K.M., Cham, M.T., Lee, J.A., Fan, G., Tan, Y.P., Yong, W.S. and Madhukumar, P., 2015. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. *Annals of Oncology*, 26(7), pp.1446-1451
- Cho, K.H., Han, E.Y., Shin, J.C., Ha, M.C., Ahn, K.H., Cho, S.H. and Im, S.H., 2022. Comparison of Clinical Symptoms and Neurophysiological Findings in Patients With Chemotherapy Induced Peripheral Neuropathy. *Frontiers in Neurology*, 13, p.838302.
- Coe, C.L., Love, G.D., Karasawa, M., Kawakami, N., Kitayama, S., Markus, H.R., Tracy, R.P. and Ryff, C.D., 2011. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. *Psychoneuroendocrinology*, 36(12), pp.1245-1254.
- Collado-Hidalgo, A., Bower, J.E., Ganz, P.A., Cole, S.W and Irwin, M.R., 2006. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. *Clinical cancer research*, 12(9), pp.2759-2766.

- Deleo, J.A., Colburn, R.W., Nichols, M. and Malhotra, A.M.I.T., 1996. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. *Journal of interferon & cytokine research*, 16(9), pp.695-700.
- Del Giudice, M. and Gangestad, S.W., 2018. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. *Brain, behavior, and immunity*, 70, pp.61-75.
- De Iuliis, F., Taglieri, L., Salerno, G., Lanza, R. and Scarpa, S., 2015. Taxane induced neuropathy in patients affected by breast cancer: literature review. *Critical reviews in oncology/hematology*, 96(1), pp.34-45.
- Desforges, A.D., Hebert, C.M., Spence, A.L., Reid, B., Dhaibar, H.A., Cruz-Topete, D., Cornett, E.M., Kaye, A.D., Urits, I. and Viswanath, O., 2022. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. *Biomedicine & Pharmacotherapy*, 147, p.112671.
- Dethlefsen, C., Højfeldt, G. and Hojman, P., 2013. The role of intratumoral and systemic IL-6 in breast cancer. *Breast cancer research and treatment*, 138(3), pp.657-664.
- Dewi Mulyani, R., Heriady, Y. and Tursina, A., 2017. Hubungan Lamanya Kemoterapi dengan Risiko Neuropati Perifer pada Pasien Kanker Payudara di RSUD Al-Ihsan Bandung. *Prosiding Pendidikan Dokter* ISSN, 2460, p.657X.
- Dougherty, P.M., Cata, J.P., Cordella, J.V., Burton, A. and Weng, H.R., 2004. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. *Pain*, 109(1-2), pp.132-142.
- Eckhoff, L., Knoop, A.S., Jensen, M.B., Ejlersen, B. and Ewertz, M., 2013. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. *Breast cancer research and treatment*, 142, pp.109-118.
- Fumagalli, G., Monza, L., Cavaletti, G., Rigolio, R. and Meregalli, C., 2021. Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. *Frontiers in immunology*, 11, p.626687.
- Gabay, C., 2006. Interleukin-6 and chronic inflammation. *Arthritis research & therapy*, 8(2), pp.1-6
- Ganz, P.A. and Dougherty, P.M., 2016. Painful hands and feet after cancer treatment: inflammation affecting the mind-body connection. *Journal of Clinical Oncology*, 34(7), pp.649-652
- Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Asghari Jafarabadi, M., Montazeri, V., Keshavarz, S.A. and Darabi, M., 2012. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo-controlled trial. *BMC cancer*, 12(1), pp.1-8.
- Goswami, B., Mittal, P. and Gupta, N., 2013. Correlation of levels of IL-6 with tumor burden and receptor status in patients of locally advanced carcinoma breast. *Indian Journal of Clinical Biochemistry*, 28, pp.90-94.

- Greenwald, M.K., Ruterbusch, J.J., Beebe-Dimmer, J.L., Simon, M.S., Albrecht, T.L. and Schwartz, A.G., 2019. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. *Cancer*, 125(2), pp.269-277.
- Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J. and Cardoso, F., 2019. Breast cancer. *Nature reviews Disease primers*, 5(1), pp.1-31.
- Hardikar, S., Song, X., Kratz, M., Anderson, G.L., Blount, P.L., Reid, B.J., Vaughan, T.L. and White, E., 2014. Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. *Cancer causes & control*, 25, pp.969-976.
- Hershman, D.L., Weimer, L.H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., Awad, D. and Crew, K.D., 2011. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. *Breast cancer research and treatment*, 125, pp.767-774.
- Hilkens, P.H.E., Verweij, J., Vecht, C.J., Stoter, G. and Van den Bent, M.J., 1997. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). *Annals of oncology*, 8(2), pp.187-190.
- Janelins, M.C., Lei, L., Netherby-Winslow, C., Kleckner, A.S., Kerns, S., Gilmore, N., Belcher, E., Thompson, B.D., Werner, Z.A., Hopkins, J.O. and Long, J., 2022. Relationships between cytokines and cognitive function from pre-to post-chemotherapy in patients with breast cancer. *Journal of neuroimmunology*, 362, p.577769.
- Jones, S., Erban, J., Overmoyer, B., Budd, G.T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W.J., Pritchard, K.I. and Mennel, R., 2005. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. *Journal of Clinical Oncology*, 23(24), pp.5542-5551.
- Kenis, G., Teunissen, C., De Jongh, R., Bosmans, E., Steinbusch, H. and Maes, M., 2002. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. *Cytokine*, 19(5), pp.228-235.
- Kiguchi, N., Maeda, T., Kobayashi, Y., Kondo, T., Ozaki, M. and Kishioka, S., 2008. The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice. *European journal of pharmacology*, 592(1-3), pp.87-92.
- Kim, M. and Jung, M.S., 2021. Effects of chemotherapy-induced peripheral neuropathy in women with breast cancer: A structural equation approach with the theory of unpleasant symptoms. *Cancer nursing*, 44(2), pp.145-153.
- Kleckner, I.R., Jusko, T.A., Culakova, E., Chung, K., Kleckner, A.S., Asare, M., Inglis, J.E., Loh, K.P., Peppone, L.J., Miller, J. and Melnik, M., 2021. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy. *Breast Cancer Research and Treatment*, 189, pp.521-532.

- Kumari, N., Dwarakanath, B.S., Das, A. and Bhatt, A.N., 2016. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumor Biology*, 37, pp.11553-11572.
- Lee, J.J. and Swain, S.M., 2006. Peripheral neuropathy induced by microtubule-stabilizing agents. *Journal of Clinical Oncology*, 24(10), pp.1633-1642.
- Lees, J.G., Makker, P.G., Tonkin, R.S., Abdulla, M., Park, S.B., Goldstein, D. and Moalem-Taylor, G., 2017. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. *European journal of cancer*, 73, pp.22-29.
- Lee, K.T., Bulls, H.W., Hoogland, A.I., James, B.W., Colon-Echevarria, C.B. and Jim, H.S., 2024. Chemotherapy-induced peripheral neuropathy (CIPN): anarrative review and proposed theoretical model. *Cancers*, 16(14), p.2571.
- Le-Rademacher, J., Kanwar, R., Seisler, D., Pachman, D.R., Qin, R., Abyzov, A., Ruddy, K.J., Banck, M.S., Lavoie Smith, E.M., Dorsey, S.G. and Aaronson, N.K., 2017. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin-and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. *Supportive Care in Cancer*, 25, pp.3537-3544.
- Lewis, M.A., Zhao, F., Jones, D., Loprinzi, C.L., Brell, J., Weiss, M. and Fisch, M.J., 2015. Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: results from a prospective multicenter study. *Journal of pain and symptom management*, 49(6), pp.1016-1024.
- Lima POD, Cunha FMB, Goncalves HD, Aires MAP, Almeida RLF, Kerr LRFS. Correlation Between Clinical Tests and Electroneuromyography for the Diagnosis of Leprosy Neuropathy. *Lepr Rev.* 2016; 87:60-70.
- Lindholm, A., Abrahamsen, M.L., Buch-Larsen, K., Marina, D., Andersson, M., Helge, J.W., Schwarz, P., Dela, F. and Gillberg, L., 2024. Pro-inflammatory cytokines increase temporarily after adjuvant treatment for breast cancer in postmenopausal women: a longitudinal study. *Breast Cancer Research*, 26(1), p.142.
- Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.C., Ruiz, A.F., Kalegari, P. and Ferbeyre, G., 2019. The senescence-associated secretory phenotype and its regulation. *Cytokine*, 117, pp.15-22.
- Loprinzi, C.L., Reeves, B.N., Dakhil, S.R., Sloan, J.A., Wolf, S.L., Burger, K.N., Kamal, A., Le-Lindqwister, N.A., Soori, G.S., Jaslowski, A.J. and Novotny, P.J., 2011. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. *Journal of Clinical Oncology*, 29(11), p.1472.
- Łukasiewicz, S., Czaczelewski, M., Forma, A., Baj, J., Sitarz, R. and Stanisławek, A., 2021. Breast cancer—epidemiology, risk faktors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers*, 13(17), p.4287.

- Ma, Y., Ren, Y., Dai, Z.J., Wu, C.J., Ji, Y.H. and Xu, J., 2017. IL-6, IL-8 and TNF- $\alpha$  levels correlate with disease stage in breast cancer patients. *Advances in Clinical and Experimental Medicine*, 26(3), pp.421-426.
- Martínez-Pérez, C., Kay, C., Meehan, J., Gray, M., Dixon, J.M. and Turnbull, A.K., 2021. The IL-6-like cytokine family: Role and biomarker potential in breast cancer. *Journal of personalized medicine*, 11(11), p.1073.
- Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi, M. and Jadidi-Niaragh, F., 2018. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. *Biomedicine & Pharmacotherapy*, 108, pp.1415-1424.
- Miyamoto, T., Hiramoto, S., Kanto, A., Tsubota, M., Fujitani, M., Fukuyama, H., Hatanaka, S., Sekiguchi, F., Koizumi, Y. and Kawabata, A., 2021. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study. *Journal of Pharmacological Sciences*, 146(1), pp.49-57.
- Mo, H., Yan, X., Zhao, F., Teng, Y., Sun, X., Lv, Z., Cao, M., Zhao, J., Song, G., Pan, B. and Li, H., 2022. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. *JAMA Network Open*, 5(11), pp.e2239788-e2239788.
- Molassiotis, A., Cheng, H.L., Lopez, V., Au, J.S., Chan, A., Bandla, A., Leung, K.T., Li, Y.C., Wong, K.H., Suen, L.K. and Chan, C.W., 2019. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. *BMC cancer*, 19(1), pp.1-19.
- Newman, L.A.; Reis-Filho, J.S.; Morrow, M.; Carey, L.A.; King, T.A. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. *Ann. Surg. Oncol.* 2014, 22, 874–882.
- New, P.Z., Jackson, C.E., Rinaldi, D., Burris, H. and Barohn, R.J., 1996. Peripheral neuropathy secondary to docetaxel (Taxotere). *Neurology*, 46(1), pp.108-111
- Omran, M., Belcher, E.K., Mohile, N.A., Kesler, S.R., Janelins, M.C., Hohmann, A.G. and Kleckner, I.R., 2021. Review of the role of the brain in chemotherapy-induced peripheral neuropathy. *Frontiers in Molecular Biosciences*, 8, p.693133.
- Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L.E., Gómez-Valles, F.O. and Ramírez-Valdespino, C.A., 2022. Subtypes of breast cancer. *Breast Cancer [Internet]*.
- Pace, A., Nisticó, C., Cuppone, F., Brià, E., Galiè, E., Graziano, G., Natoli, G., Sperduti, I., Jandolo, B., Calabretta, F. and Tomao, S., 2007. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? *Clinical breast cancer*, 7(7), pp.550-554.

- Pachman, D.R., Barton, D.L., Watson, J.C. and Loprinzi, C.L., 2011. Chemotherapy-induced peripheral neuropathy: prevention and treatment. *Clinical Pharmacology & Therapeutics*, 90(3), pp.377-387.
- Park, Y.H., Senkus-Konefka, E., Im, S.A., Pentheroudakis, G., Saji, S., Gupta, S., Iwata, H., Mastura, M.Y., Dent, R., Lu, Y.S. and Yin, Y., 2020. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. *Annals of Oncology*, 31(4), pp.451-469.
- Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN (1993) The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). *Cancer Treat Rev* 19(4):351–386
- Pereira, S., Fontes, F., Sonin, T., Dias, T., Fragoso, M., Castro-Lopes, J.M. and Lunet, N., 2016. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study. *Supportive Care in Cancer*, 24, pp.1571-1581.
- Piccolo, J. and Kolesar, J.M., 2014. Prevention and treatment of chemotherapy-induced peripheral neuropathy. *American journal of health-system pharmacy*, 71(1), pp.19-25.
- Pratama, H.A., Wibowo, S., Satiti, S. and Widayati, K., 2020. Hubungan rasio neutrofil limfosit dengan keparahan taxane induced peripheral neuropathy pada pasien kanker payudara. *Berkala NeuroSains*, 19(2), pp.63-68.
- Pusztai, L., Mendoza, T.R., Reuben, J.M., Martinez, M.M., Willey, J.S., Lara, J., Syed, A., Fritsche, H.A., Bruera, E., Booser, D. and Valero, V., 2004. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. *Cytokine*, 25(3), pp.94-102.
- Rashid, O.M., Nagahashi, M., Ramachandran, S., Graham, L., Yamada, A., Spiegel, S., Bear, H.D. and Takabe, K., 2013. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. *Surgery*, 153(6), pp.771-778.
- Said, E.A., Al-Reesi, I., Al-Shizawi, N., Jaju, S., Al-Balushi, M.S., Koh, C.Y., Al-Jabri, A.A. and Jeyaseelan, L., 2021. Defining IL-6 levels in healthy individuals: A meta-analysis. *Journal of medical virology*, 93(6), pp.3915-3924.
- Sapari, T., Abdurahman, M. and Tjandrawati, A., 2014. Kadar Interleukin-6 Serum pada Karsinoma Payudara Lanjut Lokal dan yang Bermetastasis. *Majalah Kedokteran Bandung*, 46(1), pp.15-21.
- Sastroasmoro. S, 2014. Dasar-dasar metodologi penelitian klinis. Ed 5, pp 361-371, CV Sagung Seto, Jakarta
- Simon, N.B., Danso, M.A., Alberico, T.A., Basch, E. and Bennett, A.V., 2017. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. *Quality of Life Research*, 26, pp.2763-2772.
- Singh, A., Nair, N.S., Gupta, S., Parmar, V., Prabhu, A., Hawaldar, R. and Badwe, R.A., 2022. Effect of menopausal status on chemotherapy-induced

- peripheral neuropathy: Single-institution retrospective audit. *Indian Journal of Medical and Paediatric Oncology*, 43(01), pp.068-072.
- Seretny, M., Currie, G.L., Sena, E.S., Ramnarine, S., Grant, R., MacLeod, M.R., Colvin, L.A. and Fallon, M., 2014. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Pain®*, 155(12), pp.2461-2470.
- Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K., Abe, N. and Ohtake, T., 2019. Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer. *Oncology Letters*, 17(6), pp.5139-5146.
- Sommer, C. and Kress, M., 2004. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. *Neuroscience letters*, 361(1-3), pp.184-187.
- Song, M., Wang, Y., Annex, B.H. and Popel, A.S., 2023. Experiment-based computational model predicts that IL-6 classic and trans-signaling exhibit similar potency in inducing downstream signaling in endothelial cells. *npj Systems Biology and Applications*, 9(1), p.45.
- Starkweather, A., 2010. Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment. *Nursing research and practice*, 2010.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 71(3), pp.209-249.
- Tay, N., Laakso, E.L., Schweitzer, D., Endersby, R., Vetter, I. and Starobova, H., 2022. Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients. *Frontiers in molecular biosciences*, 9, p.1015746.
- Toftagen, C., McAllister, R.D. and Visovsky, C., 2013. Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. *Journal of the advanced practitioner in oncology*, 4(4), p.204.
- Tsavaris, N.C.M.P.D., Kosmas, C., Vadiaka, M., Kanelopoulos, P. and Boulamatsis, D., 2002. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. *British journal of cancer*, 87(1), pp.21-27.
- Üceyler, N., Kafke, W., Riediger, N., He, L., Nacula, G., Toyka, K.V. and Sommer, C., 2010. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. *Neurology*, 74(22), pp.1806-1813.
- Uciechowski, P. and Dempke, W., 2020. Interleukin-6: a masterplayer in the cytokine network. *Oncology*, 98(3), pp.131-137.
- Ventzel, L., Madsen, C.S., Karlsson, P., Tankisi, H., Isak, B., Fuglsang-Frederiksen, A., Jensen, A.B., Jensen, A.R., Jensen, T.S. and Finnerup, N.B., 2018. Chronic pain and neuropathy following adjuvant chemotherapy. *Pain medicine*, 19(9), pp.1813-1824

- Vgontzas, A.N., Bixler, E.O., Lin, H.M., Prolo, P., Trakada, G. and Chrousos, G.P., 2005. IL-6 and its circadian secretion in humans. *Neuroimmunomodulation*, 12(3), pp.131-140.
- Waks, A.G. and Winer, E.P., 2019. Breast cancer treatment: a review. *Jama*, 321(3), pp.288-300.
- Wang, X.M., Lehky, T.J., Brelvi, J.M. and Dorsey, S.G., 2012. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. *Cytokine*, 59(1), pp.3-9.
- Windebank AJ, Grisold W. 2008. Chemotherapy-induced neuropathy. *J Peripher New Syst*, 13, pp.27-46.
- Xu, H., Li, H., Fan, Y., Wang, Y., Li, Z., Zhou, L. and Hao, X., 2025. Analysis of factors influencing chemotherapy-induced peripheral neuropathy in breast cancer patients using a random forest model. *The Breast*, 81, p.104457.
- Zhang, J.M. and An, J., 2007. Cytokines, inflammation, and pain. *International anesthesiology clinics*, 45(2), p.27.
- Zhang, J., Wang, J., Gong, Y., Gu, Y., Xiang, Q. and Tang, L.L., 2022. Interleukin-6 and granulocyte colony-stimulating factor as predictors of the prognosis of influenza-associated pneumonia. *BMC infectious diseases*, 22(1), p.343.
- Zhang, X., Chen, W.W., and Huang, W.J., 2017. Chemotherapy-induced peripheral neuropathy. *Biomedical reports*, 6(3), pp.267-271.
- Zhou, Y.Q., Liu, Z., Liu, Z.H., Chen, S.P., Li, M., Shahveranov, A., Ye, D.W. and Tian, Y.K., 2016. Interleukin-6: an emerging regulator of pathological pain. *Journal of neuroinflammation*, 13(1), pp.1-9
- Zhu, H. and Doğan, B.E., 2021. American Joint committee on cancer's staging system for breast cancer: summary for clinicians. *European journal of breast health*, 17(3), p.234